Endothelial progenitor cells (EPCs) are thought to be important for maintaining normal vascular function. We conducted a prospective study evaluating the effect of the erythropoiesis-stimulating agent darbepoetin alfa on EPCs and vascular function in patients with chronic kidney disease (CKD), with or without diabetes. Thirty subjects with CKD (20 subjects with type II diabetes mellitus and 10 without diabetes mellitus) received weekly subcutaneous administration of darbepoetin alfa for 4 weeks. EPCs were measured at baseline and 2 and 4 weeks after drug administration. Vascular function was measured with brachial ultrasound and cell activity was measured with a cell proliferation assay. Cells expressing CD133, CD34, CD146 and CD146/31 were significantly elevated (all p < 0.05), flow-mediated vasodilatation increased 2.1%, 95% CI: (0.4%, 3.8%) and colony-forming units increased twofold, 95% CI: (1.7, 2.3) after 4 weeks of treatment with darbepoetin alfa. Subjects with diabetes exhibited an increase in a subset of EPCs (CD133 + and 34 + , p < 0.01 and p = 0.06, respectively), vasodilatation and proliferation. In conclusion, the administration of darbepoetin alfa for 4 weeks increased a subset of EPCs, improved endothelial function and increased cell proliferation, including those with diabetes, which is consistent with a favorable improvement in vascular health.
Introduction
Patients with chronic kidney disease (CKD) have a high cardiovascular morbidity and mortality, and most die of complications related to atherosclerosis, namely myocardial infarction and stroke. 1, 2 Vascular repair mechanisms in patients with CKD are poorly understood. Bone marrowderived endothelial progenitor cells (EPCs) are involved in the reparative processes of the cardiovascular system. 3, 4 EPCs originate from CD34 positive hematopoietic stem cells, which differentiate via separate pathways into erythrocytes, thrombocytes, various lineages of leukocytes, and endothelial cells. EPCs circulate in the vasculature, where they home and incorporate into sites of active neo-vascularization. 5, 6 In patients with coronary artery disease, the number of EPCs inversely correlates with the number of cardiovascular risk factors 7 and the degree of endothelial dysfunction. 8 Anemia in patients with CKD is to a large extent secondary to reduced erythropoietin synthesis by peritubular fibroblast-like cells of the kidney. A series of studies indicates that administration of recombinant human erythropoietin (rhEPO) or its analogue darbepoetin alfa enhances EPC differentiation in vitro and in vivo. 9, 10 In addition, studies in laboratory animals indicate that rhEPO mobilizes EPCs from the bone marrow. 11 The diabetic state, common in patients with CKD, results in impaired endothelial function and reduced levels of circulating EPCs. 12, 13 Clinical studies with erythropoiesis-stimulating agents (ESAs) aimed at normalizing hemoglobin levels have been disappointing from a cardiovascular standpoint and may even increase risk of stroke. [14] [15] [16] [17] A subnormal level of hemoglobin with low-dose ESA use has been postulated as having a safer clinical cardiovascular profile than higher hemoglobin levels in the normal range and use of higher ESA doses. The hypothesis of the present study is that impaired function of EPCs due to erythropoietin deficiency is a potential cardiovascular risk factor contributing to morbidity and mortality in patients with CKD and the vascular system will be improved with administration of an ESA to target a subnormal hemoglobin level. We conducted a prospective study evaluating EPCs and vascular function in patients with CKD, with or without diabetes, in response to administration of darbepoetin alfa.
Subjects and methods
Thirty subjects with CKD, 20 subjects with type II diabetes mellitus and 10 without diabetes mellitus, received darbepoetin alfa by subcutaneous injection at a dose of 0.45 mcg/kg (rounded to nearest 10 mcg) weekly for 4 weeks. Inclusion criteria were males (21 years of age or greater) and post-menopausal females between the ages of 45 and 75 years, Stage 3-5 CKD based on Modification of Diet in Renal Disease (MDRD) (modified) calculation (GFR < 59 ml/min/1.73 m 2 ) not on dialysis and anemia due to CKD with hemoglobin < 11.0 mg/dl. Exclusion criteria included uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg), liver function test abnormalities (AST or ALT > 2.5 × upper limit of normal), excessive alcohol intake as defined by > 15 drinks per week, a significant medical or psychiatric condition that in the opinion of the investigator would preclude the safety of a subject, and the presence of other causes of anemia including iron deficiency (defined as transferrin saturation of iron < 15%). Patients taking a HMG-CoA reductase inhibitor (statin) must have been on a stable dose for at least 2 months prior to enrollment. Once enrolled into the study, if not already on a statin, patients were not allowed to start statin therapy.
Darbepoetin alfa was chosen as it is currently a widely prescribed drug for patients with CKD and has been previously shown to activate endothelial Akt. 9 Blood was obtained from all of the patients for measurement of circulating EPCs at baseline prior to receiving darbepoetin alfa and then at 2 weeks and 4 weeks after drug initiation. Blood was also obtained at baseline and 4 weeks after drug initiation for EPC functional cell culture studies. In order to assess EPC function, the number of colony-forming units (CFUs), an indirect measure of circulating EPCs, was quantified using a commercially available assay (EndoCult ® medium; Stem Cell Technologies, Vancouver, BC, Canada). Brachial artery reactivity to assess endothelial-dependent vasoreactivity was performed at baseline prior to darbepoetin alfa administration and 4 weeks later.
Cytometric assay for circulating EPCs
There is no uniform definition of an EPC as various cell surface markers have been used to characterize these cells. 18 The reason for this non-uniformity is in part due to constraints of commonly used flow cytometry instrumentation that only have a relatively small number of detectors available for cell characterization. Flow cytometry for such rare events requires exquisite attention to technical detail, including both viability markers and negative selection markers in addition to the actual positive markers. Using instruments with limited detector capacity also does not allow for simultaneous assessment of the number of mature circulating endothelial cells. We developed a sensitive flow cytometric assay to identify circulating EPCs and mature endothelial cells using a high dimensional flow cytometer capable of detecting 11 fluorescence signals and two light scatter signals. This approach provides enhanced sensitivity and specificity for circulating endothelial cells of all levels of maturity. 19 Data were collected on a modified BD FACS Canto (BD Biosciences, San Jose, CA, USA) flow cytometer. The flow cytometry 5-color antibody panel assay consisted of: FITCanti-CD31 (PECAM), PE-anti-CD146, PE-anti-CD133, PerCP-Cy5.5-anti-CD3,-CD19,-CD33, PE-Cy7-anti-CD34, and APC-anti-VEGF-R2. 19 Viability was assessed by propidium iodide exclusion resulting in a six-color assay. The gating strategy selected viable, low side scatter singlets that were negative for CD3, CD19 and CD33 lineage markers (online only -Supplementary Figure S1 ). Analysis focused on immature cells (CD133 + ), hematopoietic progenitors (CD133 + / CD34 + and CD34 + ), EPCs (CD133 + /34 + /VEGF-R2 + ), and mature endothelial cells (CD146 + /CD31 + ). Cell populations were quantified based on a percentage of mononuclear cells calculated per ml of blood, and analyzed using FlowJo analytical software (Treestar, Ashland, OR, USA).
Colony-forming assay
In addition to flow cytometric measurements, in vitro culture studies were performed to evaluate colony formation from mononuclear cells. Mononuclear cells were prepared by light density separation using Ficoll-Paque™ PLUS (Stem Cell Technologies, catalog #07957). The cells were washed twice with 3% FBS/PBS and resuspended in EndoCult medium. A total of 5 × 10 6 mononuclear cells were plated per well in the six-well fibronectin-coated plate (BD Biosciences, catalog #354402) in duplicate and incubated for 2 days at 37°C, 5% CO 2 with ≥ 95% humidity. After 2 days, the non-adherent cells from each well were transferred into individual 5-ml tubes. Afterwards, 1 × 10 6 cells/well were plated in duplicate in a 24-well fibronectincoated plate (BD Biosciences, catalog #354411). Fresh EndoCult liquid medium was then added to a final volume of 1.0-ml per well. The cells were then incubated at 37°C, 5% CO 2 with ≥ 95% humidity for 3 days. At day 5 of the assay, the number of CFUs was counted for each sample. A CFU was defined as a central core of round cells, with radiating elongated spindle-like cells at the periphery.
Endothelial function assessment
Endothelial-dependent vasodilatation was assessed using the brachial artery reactivity test as per American Society of Echocardiography/Society for Vascular Medicine and Biology guidelines. 20 In brief, after an overnight fast and at 8 a.m. the next morning, subjects underwent ultrasound imaging of the brachial artery using a Siemens ultrasound machine with a 9L4 probe. A digital image clip, gated to the R-wave of the cardiac cycle, was obtained at baseline. A blood pressure cuff positioned over the bicep muscle was then inflated for 5 minutes with complete occlusion and then released resulting in ischemia. Another digital ultrasound clip was obtained 1 minute after cuff deflation. Fifteen minutes thereafter, another baseline image clip was obtained. Sublingual nitroglycerin (0.4 mg) was then administered and an image clip was obtained 5 minutes later. The images were analyzed offline with FDA-approved and validated commercial software (Medical Imaging Applications, Iowa City, IA, USA). An independent observer blinded to the clinical details of the patient measured the diameter of the vessel.
Complete blood count and white blood count differentiation analysis
Blood cell analysis was performed using a COULTER ® LH 780 Hematology Analyzer (Beckman Coulter, Brea, CA, USA) following the manufacturer's protocol.
Statistical analysis
Subject characteristics at baseline were summarized using medians and inter-quartile ranges or counts and percentages, as appropriate; differences across diabetic and non-diabetic groups were assessed using either an exact Wilcoxon rank sum test or Fisher's exact test. The number of lymphocytes, number of mononuclear cells, hemoglobin concentration, and red blood cell counts exhibited a symmetric distribution. Therefore, linear regression models were used to estimate the mean difference over time for diabetic and non-diabetic groups. Flow cytometric cell subsets were explored using graphical and numerical summaries. For several surface markers, an overwhelming proportion of subjects exhibited zero counts, which precluded formal statistical analyses regarding change in these subsets over time. The remaining subsets exhibited a skewed distribution and were log-transformed. Linear regression models for the log-transformed counts were used such that the exponentiated regression coefficients corresponded to the ratio of mean counts over time.
A log-linear regression model was used to analyze the number of CFUs. In all regression models, subject-specific random intercepts were used to account for the correlation due to repeated measurements. A p-value < 0.05 was considered statistically significant. All statistical analyses were performed using R (R Development Core Team, Vienna, Austria).
Results

Patient demographics
Thirty subjects were recruited into the study (Table 1 ). There was no significant difference in age or sex between the diabetic and non-diabetic group. The prevalence of coronary artery disease, peripheral artery disease and smoking was higher in patients with diabetes. The number of lymphocytes and mononuclear cells at 2 and 4 weeks after darbepoetin alfa administration was not significantly different from baseline for all subjects together or when analyzed according to diabetes status (online only -Supplementary Figure S2 ). The absence of a significant change in white blood cell count indicates that any change in EPCs was not due to a global increase in white cells. As expected, the hemoglobin concentration and number of red blood cells significantly increased in both study populations after 4 weeks of darbepoetin alfa treatment (online only -Supplementary Figure S3 ).
Circulating EPCs and mature endothelial cells
The number of circulating EPCs was measured at baseline and after administration of darbepoetin alfa for 4 weeks.
Among all study patients, CD133 and CD34 positive cells were significantly elevated after 4 weeks of treatment ( Table 2 ). Other cells positive for the aforementioned surface EPC markers either alone or in combination were not present or did not change significantly after 4 weeks of darbepoetin alfa treatment. There was an increase in CD133 + and CD34 + cells in the diabetic group but not in the nondiabetic group. At baseline, the absolute number of EPCs in the diabetic group was lower than in the non-diabetic group, although the differences were not statistically significant.
There was no association between EPCs and hemoglobin concentration. Cells expressing both mature endothelial cell markers CD146 and CD31 were significantly increased after 4 weeks of darbepoetin treatment when considering all study patients together ( Table 2 ). The diabetic group did not show a significant elevation of CD31 + and CD146 + cells, whereas these cells were significantly increased in the non-diabetic Figure 2 . Flow-mediated vasodilatation at baseline and week 4 for subjects with and without diabetes mellitus; mean and 95% confidence interval. Difference in mean FMD between week 4 versus baseline: All subjects: 2.07%, 95% CI: (0.37%, 3.78%), p = 0.02; Diabetics: 2.33%, 95% CI: (0.37%, 4.28%), p = 0.02; Non-diabetics: 1.74%, 95% CI: (-1.43%, 4.92%), p = 0.27.
group. Other surface marker combinations did not show a significant change after treatment.
Function status of endothelial progenitor cells
After the 5-day cell culture, CFUs were counted for each blood sample. After 4 weeks of treatment with darbepoetin alfa, a significant increase in CFUs was observed when all study patients were analyzed together ( Figure 1 ) and in each separate study group.
Endothelial function
Flow-mediated vasodilatation (FMD) assessed with brachial artery ultrasound was evaluated at baseline and after 4 weeks of darbepoetin treatment. FMD increased with darbepoetin treatment in the study population as a whole (Figure 2) . A significant increase in FMD was noted in the diabetic group but the increase in FMD in non-diabetic subjects was not statistically significant.
Discussion
To our knowledge, this is the first report assessing the effect of darbepoetin alfa on circulating EPC levels, EPC function and vascular reactivity. The weekly administration of darbepoetin over 4 weeks increased a subset of EPCs (CD34 + , CD133 + ), increased activity in cell culture and correlated with improvement in endothelial function. The patients with CKD and diabetes showed an increase in CD133 + and CD34 + cells, indicating that darbepoetin alfa promotes an EPC increase in the diabetic state. There was also a significant positive effect of darbepoetin alfa on circulating mature endothelial cells.
EPCs and kidney disease
Studies of patients on hemodialysis and patients with CKD have shown alterations in the number of circulating EPCs as well as functional impairment of EPCs. The results are mixed as both increased and decreased EPCs have been reported for such patients; 21, 22 the reasons for this discrepancy are not known. Functional impairment in cell activity as shown with reduced EPC differentiation, migration, and adhesion has been described in hemodialysis patients. 21, 23 There are relatively few data published regarding EPCs in patients with CKD who are not on dialysis. A cell culturebased assessment of circulating EPCs found that patients with advanced renal failure had significantly fewer EPCs than healthy controls. 24 The importance of EPCs as a predictor of atherogenic burden was studied in patients enrolled in the Framingham study where a lower CFU number was associated with a higher burden of subclinical atherosclerosis in coronary arteries and aorta. 25 However, the biological significance of CFUs is unclear in regards to endothelial regeneration. 26 A study of a mixed population of patients with varying degrees of CKD, including patients on hemodialysis and peritoneal dialysis, found a reduction in EPC number and function with worsening kidney disease. 27 The administration of hormones such as rhEPO [9] [10] [11] and drugs such as HMG-CoA reductase inhibitors 7, 28, 29 increase the circulating pool of EPCs, supposedly via increased mobilization from bone marrow. As demonstrated in the present study, impairment of EPCs in the setting of decreased glomerular filtration rate does not appear permanent as EPC levels increased in response to short-term (4-week) darbepoetin alfa administration. It is also plausible that the increase in circulating mature endothelial cells may be secondary to darbepoetin alfa stimulation of progenitor cells residing outside the marrow. 18, 30 
Effect of diabetes on EPCs
Animal studies and cell culture studies in humans suggest that diabetes mellitus impairs EPC number and function, which may explain the reduced angiogenic response in patients observed with diabetes. 12, 31 Conceptually, endothelial health and the angiogenic response may be enhanced through mobilization of EPCs from the bone marrow, putatively via the Akt-nitric oxide pathway, as demonstrated with in vitro studies of statin drugs 32 and rhEPO. 33 Given the increased amount of oxidative stress and reduced availability of nitric oxide in patients with diabetes, it was unclear before the current study whether EPCs and vascular function would improve with erythropoietin analogue treatment, despite the diabetic state. The current study findings suggest that poor vascular health in patients with diabetes and CKD is partially reversible and improved with darbepoetin alfa treatment.
CKD and vascular function
The clinical importance of EPCs in maintaining vascular health in patients with CKD is becoming evident. The presence of CKD is an independent risk factor for reduced progenitor cell mobilization and progenitor cell dysfunction and there are limited data documenting its related association with cardiovascular outcome. One study of 77 patients on hemodialysis found that reduced levels of CD34/ VEGFR2 + cells was associated with a hazard ratio of 3.9 for vascular events after adjustment for traditional risk factors. 34 Therapeutic strategies are now being tested to determine if increasing EPCs improve vascular health. A study using a pig model of chronic renal artery stenosis showed that a single intrarenal infusion of autologous EPCs preserved microvascular architecture and function and decreased microvascular remodeling. 35 The current study results suggest that the ESA darbepoetin alfa may improve vascular function in CKD patients through effects on EPCs. The study is, however, limited by the lack of a control group and an inadequate number of non-diabetic subjects.
The clinical impact of long-term treatment with erythropoietin analogues was evaluated in three studies. [14] [15] [16] [17] The cumulative results of these studies indicate that targeting a hemoglobin in the normal range (13.0-15.0 g per deciliter) does not reduce cardiovascular events in patients with CKD who are not on dialysis, and may increase risk of stroke. The hemoglobin level attained in the present study patients was less than 12.0 g per deciliter, which is lower than the mean hemoglobin concentration reported in these studies as a consequence of the short-term exposure in our study and of the low dose of darbepoetin alfa. Despite this, the darbepoetin alfa exposure was still sufficient to stimulate EPC release from the bone marrow; it was beyond the scope of this study to determine the effect of darbepoetin alfa on EPC release over a longer follow-up period. Further study is needed to determine if the putative benefit of increased circulating EPCs is enough to offset the increased risk of adverse cardiovascular events seen in patients with CKD and if low doses of ESAs can confer beneficial cardiovascular effects through EPC stimulation without exposing patients to potentially harmful effects of high hemoglobin levels and ESA doses.
Conclusions
The present study supports the hypothesis that in patients with CKD, EPCs are increased with the ESA darbepoetin alfa, even in the setting of diabetes. The increased responsiveness of EPCs may be responsible for improved vascular function.
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